Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3999MR)

This product GTTS-WQ3999MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3999MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14457MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ7122MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ400MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ886MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ12550MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ13958MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ11636MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ9601MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW